Skip to main content
Erschienen in:

23.03.2020 | Gynecologic Oncology

Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study

verfasst von: Koji Matsuo, Rachel S. Mandelbaum, Hiroko Machida, Kosuke Yoshihara, Shinya Matsuzaki, Maximilian Klar, Franco M. Muggia, Lynda D. Roman, Jason D. Wright

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To examine trends, characteristics and outcomes of women who develop both ovarian and breast cancers.

Methods

This is a retrospective study examining the Surveillance, Epidemiology, and End Results Program from 1973 to 2013. Among ovarian cancer (n = 133,149) and breast cancer (n = 1,143,219) cohorts, women with both diagnoses were identified and temporal trends, tumor characteristics and survival were examined.

Results

There were 6446 women with both malignancies, representing 4.8% of the ovarian cancer cohort and 0.6% of the breast cancer cohort. Women with ovarian cancer who had secondary breast cancer were younger than those without secondary breast cancer early in the study period (52.3 versus 59.2 in 1973) but older in more recent years (68.5 versus 62.1 in 2013, P < 0.001). The number of breast cancer survivors who developed postcedent ovarian cancer decreased from 1.5 to 0.2% from 1979 to 2008 (relative risk reduction 90.0%, P < 0.05). Similarly, the number of ovarian cancer survivors who developed postcedent breast cancer decreased from 7.2 to 2.0% from 1973 to 2008 (relative risk reduction 72.4%, P < 0.05). Tumor characteristics were more likely to be favorable in women with ovarian cancer who developed postcedent breast cancer but unfavorable in those who had antecedent breast cancer (all, P < 0.05). Women with ovarian cancer who had secondary breast cancer had superior cause-specific survival compared to those who did not develop breast cancer regardless of breast cancer timing (P < 0.05).

Conclusion

Our study demonstrated that the demographics of women who develop breast cancer and ovarian cancer have changed over time and diagnosis of secondary breast cancer after ovarian cancer has decreased.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.CrossRef
2.
Zurück zum Zitat Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome (2017) Obstet Gynecol 130:e110–e126. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome (2017) Obstet Gynecol 130:e110–e126.
3.
Zurück zum Zitat Molina-Montes E, Requena M, Sanchez-Cantalejo E, Fernandez MF, Arroyo-Morales M, Espin J, Arrebola JP, Sanchez MJ (2015) Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol Oncol 136:158–171CrossRef Molina-Montes E, Requena M, Sanchez-Cantalejo E, Fernandez MF, Arroyo-Morales M, Espin J, Arrebola JP, Sanchez MJ (2015) Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol Oncol 136:158–171CrossRef
4.
Zurück zum Zitat Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118:2285–2292CrossRef Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118:2285–2292CrossRef
5.
Zurück zum Zitat Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A (2008) Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 98:870–874CrossRef Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A (2008) Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 98:870–874CrossRef
6.
Zurück zum Zitat McGuire V, Whittemore AS, Norris R, Oakley-Girvan I (2000) Survival in epithelial ovarian cancer patients with prior breast cancer. Am J Epidemiol 152:528–532CrossRef McGuire V, Whittemore AS, Norris R, Oakley-Girvan I (2000) Survival in epithelial ovarian cancer patients with prior breast cancer. Am J Epidemiol 152:528–532CrossRef
7.
Zurück zum Zitat Li Z, Wu Q, Song J, Zhang Y, Zhu S, Sun S (2018) Risk of second primary female genital malignancies in women with breast cancer: a SEER Analysis. Horm Cancer 9:197–204CrossRef Li Z, Wu Q, Song J, Zhang Y, Zhu S, Sun S (2018) Risk of second primary female genital malignancies in women with breast cancer: a SEER Analysis. Horm Cancer 9:197–204CrossRef
8.
Zurück zum Zitat Hall HI, Jamison P, Weir HK (2001) Second primary ovarian cancer among women diagnosed previously with cancer. Cancer Epidemiol Biomarkers Prev 10:995–999PubMed Hall HI, Jamison P, Weir HK (2001) Second primary ovarian cancer among women diagnosed previously with cancer. Cancer Epidemiol Biomarkers Prev 10:995–999PubMed
9.
Zurück zum Zitat Schonfeld SJ, de Gonzalez BA, Visvanathan K, Pfeiffer RM, Anderson WF (2013) Declining second primary ovarian cancer after first primary breast cancer. J Clin Oncol 31:738–743CrossRef Schonfeld SJ, de Gonzalez BA, Visvanathan K, Pfeiffer RM, Anderson WF (2013) Declining second primary ovarian cancer after first primary breast cancer. J Clin Oncol 31:738–743CrossRef
10.
Zurück zum Zitat Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M (2013) Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer 119:1344–1348CrossRef Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M (2013) Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer 119:1344–1348CrossRef
11.
Zurück zum Zitat Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF (2014) Breast cancer following ovarian cancer in BRCA mutation carriers. JAMA Surg 149:1306–1313CrossRef Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF (2014) Breast cancer following ovarian cancer in BRCA mutation carriers. JAMA Surg 149:1306–1313CrossRef
12.
Zurück zum Zitat Vencken PM, Kriege M, Hooning M, Menke-Pluymers MB, Heemskerk-Gerritsen BA, van Doorn LC, Collee MM, Jager A, van Montfort C, Burger CW, Seynaeve C (2013) The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling. Cancer 119:955–962CrossRef Vencken PM, Kriege M, Hooning M, Menke-Pluymers MB, Heemskerk-Gerritsen BA, van Doorn LC, Collee MM, Jager A, van Montfort C, Burger CW, Seynaeve C (2013) The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling. Cancer 119:955–962CrossRef
13.
Zurück zum Zitat McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA (2017) Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? Gynecol Oncol 145:346–351CrossRef McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA (2017) Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? Gynecol Oncol 145:346–351CrossRef
14.
Zurück zum Zitat Hunter MI, Ziogas A, Flores F, Brewster WR (2007) Epithelial ovarian cancer and low malignant potential (LMP) tumors associated with a lower incidence of second primary breast cancer. Am J Clin Oncol 30:1–7CrossRef Hunter MI, Ziogas A, Flores F, Brewster WR (2007) Epithelial ovarian cancer and low malignant potential (LMP) tumors associated with a lower incidence of second primary breast cancer. Am J Clin Oncol 30:1–7CrossRef
15.
Zurück zum Zitat Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, Dotson WD, Bowen MS, Khoury MJ (2018) Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. Genet Med 20:428–434CrossRef Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, Dotson WD, Bowen MS, Khoury MJ (2018) Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. Genet Med 20:428–434CrossRef
20.
Zurück zum Zitat Matsuo K, Machida H, Stone RL, Soliman PT, Thaker PH, Roman LD, Wright JD (2017) Risk of subsequent ovarian cancer after ovarian conservation in young women with stage I endometrioid endometrial cancer. Obstet Gynecol 130:403–410CrossRef Matsuo K, Machida H, Stone RL, Soliman PT, Thaker PH, Roman LD, Wright JD (2017) Risk of subsequent ovarian cancer after ovarian conservation in young women with stage I endometrioid endometrial cancer. Obstet Gynecol 130:403–410CrossRef
21.
Zurück zum Zitat Matsuo K, Machida H, Blake EA, Holman LL, Rimel BJ, Roman LD, Wright JD (2018) Trends and outcomes of women with synchronous endometrial and ovarian cancer. Oncotarget 9:28757–28771PubMedPubMedCentral Matsuo K, Machida H, Blake EA, Holman LL, Rimel BJ, Roman LD, Wright JD (2018) Trends and outcomes of women with synchronous endometrial and ovarian cancer. Oncotarget 9:28757–28771PubMedPubMedCentral
22.
Zurück zum Zitat Italian Cancer Figures (2014) Report 2013: multiple tumours. Epidemiol Prev 37:1–152 Italian Cancer Figures (2014) Report 2013: multiple tumours. Epidemiol Prev 37:1–152
23.
Zurück zum Zitat Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM (2012) Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 118:3087–3094CrossRef Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM (2012) Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 118:3087–3094CrossRef
24.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York
26.
Zurück zum Zitat Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351CrossRef Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351CrossRef
28.
Zurück zum Zitat Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Grande E, Zigon G, Brenner H (2009) Multiple tumours in survival estimates. Eur J Cancer 45:1080–1094CrossRef Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Grande E, Zigon G, Brenner H (2009) Multiple tumours in survival estimates. Eur J Cancer 45:1080–1094CrossRef
29.
Zurück zum Zitat von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806–808CrossRef von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806–808CrossRef
31.
Zurück zum Zitat Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, Kim-Sing C, Tung N, Friedman S, Senter L, Weitzel J, Karlan B, Moller P, Sun P, Narod SA (2015) Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer 137:1136–1146CrossRef Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, Kim-Sing C, Tung N, Friedman S, Senter L, Weitzel J, Karlan B, Moller P, Sun P, Narod SA (2015) Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer 137:1136–1146CrossRef
32.
Zurück zum Zitat Primas H, Kroiss R, Kalteis K, Rappaport C, Muhr D, Primas C, Kubista E, Horvat R, Oefner P, Singer WC, The Austrian Hereditary B, Ovarian Cancer Group T (2012) Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers. Eur J Cancer Prev 21(199):204 Primas H, Kroiss R, Kalteis K, Rappaport C, Muhr D, Primas C, Kubista E, Horvat R, Oefner P, Singer WC, The Austrian Hereditary B, Ovarian Cancer Group T (2012) Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers. Eur J Cancer Prev 21(199):204
33.
Zurück zum Zitat Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23:7491–7496CrossRef Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23:7491–7496CrossRef
34.
Zurück zum Zitat Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, Borowsky ME, Gibb RK (2015) Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 121:2108–2120CrossRef Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, Borowsky ME, Gibb RK (2015) Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 121:2108–2120CrossRef
35.
Zurück zum Zitat Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792CrossRef Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792CrossRef
36.
Zurück zum Zitat Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684–1689CrossRef Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684–1689CrossRef
37.
Zurück zum Zitat Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260–2265CrossRef Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260–2265CrossRef
38.
Zurück zum Zitat Matsuo K, Mandelbaum RS, Machida H, Yoshihara K, Muggia FM, Roman LD, Wright JD (2019) Decreasing secondary primary uterine cancer after breast cancer: a population-based analysis. Gynecol Oncol (In Press) Matsuo K, Mandelbaum RS, Machida H, Yoshihara K, Muggia FM, Roman LD, Wright JD (2019) Decreasing secondary primary uterine cancer after breast cancer: a population-based analysis. Gynecol Oncol (In Press)
39.
Zurück zum Zitat Matsuo K, Mandelbaum RS, Machida H, Yoshihara K, Muggia FM, Roman LD, Wright JD (2019) Decreasing trends of secondary primary colorectal cancer among women with uterine cancer: a population-based analysis. J Clin Med 8:714CrossRef Matsuo K, Mandelbaum RS, Machida H, Yoshihara K, Muggia FM, Roman LD, Wright JD (2019) Decreasing trends of secondary primary colorectal cancer among women with uterine cancer: a population-based analysis. J Clin Med 8:714CrossRef
Metadaten
Titel
Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study
verfasst von
Koji Matsuo
Rachel S. Mandelbaum
Hiroko Machida
Kosuke Yoshihara
Shinya Matsuzaki
Maximilian Klar
Franco M. Muggia
Lynda D. Roman
Jason D. Wright
Publikationsdatum
23.03.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2020
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-020-05508-3

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Einer von sieben Frauen macht die Menopause sehr zu schaffen

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Keine eingeschränkten Kassenleistungen bei Schwangerschaft nach IVF

Nach privat bezahlter In-vitro-Fertilisation muss die gesetzliche Krankenkasse ein Arzneimittel zum Erhalt der Schwangerschaft bezahlen, so ein Urteil des Sozialgerichts in München.

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.